Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 13,118 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06079671RecruitingPhase 3
Volrustomig for high-risk locally advanced cervical cancer
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
Birmingham, AlabamaAges 15 years+ - NCT06418594RecruitingPhase 2
Drug combo for HER2-negative breast cancer brain metastasis
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06340230RecruitingPhase 2
New drug combination before surgery for HR+ HER2-low breast cancer
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
Shenyang, LiaoningAges 18–75 - NCT06434597RecruitingPhase 2
Study of SPH5030 for HER2-positive advanced colorectal or bile duct cancer
This study tests a new medication (SPH5030) for people with advanced colorectal or biliary tract cancer whose tumors have a specific marker called HER2. It may offer a treatment option if previous therapies have stopped working.
BeijingAges 18 years+ - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Phoenix, ArizonaAges 18 years+ - NCT06338683RecruitingPhase 3
Olanzapine for advanced upper digestive and lung cancer survival
This study tests whether a medicine called olanzapine can improve survival in people with advanced cancers of the upper digestive system or lungs. Olanzapine may help with appetite and weight, which are common problems in these cancers.
Xining, QinghaiAges 18–80 - NCT06368063RecruitingPhase 4
Huaier granules after pancreatic cancer surgery
This trial tests whether a Chinese herbal medicine called Huaier granules works better than standard chemotherapy for people with pancreatic cancer that was removed by surgery. Participants can choose to take Huaier granules or standard chemotherapy, and researchers will compare outcomes.
Xi'an, ShannxiAges 18–80 - NCT06329856Recruiting
Hydration for terminal cancer patients in Taiwan
This study surveys hospice doctors in Taiwan to understand when and why they give artificial hydration to terminally ill cancer patients. It may help improve care for people at the end of life.
TaipeiAges Any age - NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75 - NCT06420115Recruiting
Comparing needle sizes for prostate MRI-targeted biopsy
This study compares two different needle sizes used during a prostate biopsy to see which one finds cancer more accurately and causes fewer side effects. It is for people who have not been diagnosed with prostate cancer before and have a suspicious MRI finding.
Padua, ItalyAges 18 years+ - NCT06387810RecruitingPhase 2
Chemo before and after surgery for borderline resectable pancreatic cancer
This trial tests a combination of chemotherapy drugs (irinotecan liposome, 5-FU, leucovorin, and oxaliplatin) given before and after surgery for people with pancreatic cancer that is on the border of being removable. The goal is to see if this treatment helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–110 - NCT06141265RecruitingPhase 2
Niraparib maintenance after chemo and Avastin for advanced ovarian cancer
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
Beijing, Beijing MunicipalityAges 18–75 - NCT06866938RecruitingPhase 2
Second course of PSMA-targeted radiation for prostate cancer
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
BordeauxAges 18 years+ - NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
Sarasota, FloridaAges 18 years+ - NCT05416775RecruitingPhase 1/Phase 2
Test drug SHR-8068 for advanced lung cancer
This trial tests SHR-8068 in people with advanced non-small cell lung cancer (NSCLC). It may help by controlling cancer after standard treatments have not worked, and it’s designed to find the right way to give the drug.
Hefei, AnhuiAges 18–75 - NCT06409910RecruitingPhase 2
Comparing shorter radiation treatments for prostate cancer
This study tests two slightly different short-course radiation schedules for men who have had their prostate removed and are now getting follow-up radiation. The goal is to see if one is more effective or has fewer side effects.
London, OntarioAges 18 years+ - NCT03419689Recruiting
Study checks blood and tumor markers in advanced ovarian cancer
This study looks at “biomarkers,” meaning measurable signals in blood and tumor tissue, in people with advanced ovarian-type cancers. The goal is to understand these markers and how they relate to the cancer, which may help guide future care.
Barrie, OntarioAges 18 years+ - NCT07314801Enrolling by invitation
Financial impact of cancer in young adults
This study looks at how cancer treatment affects your finances and your recovery, especially for young adults. It involves a phone interview and some questionnaires to understand your experience.
Göttingen, Lower SaxonyAges 18–50 - NCT06830850RecruitingPhase 1
Testing a new drug for metastatic prostate cancer
This trial tests a new drug, HRS-5041, for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the drug is safe and can help control the cancer.
Sydney, New South WalesAges 18 years+ - NCT06440902RecruitingPhase 2
New treatments for RAS-changed colorectal cancer using blood tests
This study tests new treatment plans for people with metastatic colorectal cancer whose tumors originally had a RAS mutation but later show no RAS mutation in blood tests. The goal is to see if these treatment changes can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06362577Recruiting
HIFU vs Robot Surgery for Localized Prostate Cancer
This trial compares two treatments for localized prostate cancer: high-intensity focused ultrasound (HIFU) using a device called Sonablate and robot-assisted surgery. It aims to see which works better and has fewer side effects.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT07299825RecruitingPhase 2
Study of A166 for advanced HER2-positive breast cancer
This trial tests a new drug called A166 for people with HER2-positive breast cancer that has spread or can't be removed. It is for those who have already tried up to five treatments, including a specific type of HER2 antibody-drug conjugate.
Zhenzhou, HenanAges 18–75 - NCT07616440Recruiting
Ultrasound drug delivery with chemotherapy for HER2-positive breast cancer
This study tests a new technique that uses focused ultrasound to deliver cancer drugs directly to breast tumors, combined with standard chemotherapy. The goal is to improve treatment effectiveness for HER2-positive breast cancer before surgery.
Hangzhou, ZhejiangAges 18–70 - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 13,118 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.